Wisconsin 2023-2024 Regular Session

Wisconsin Assembly Bill AB753 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	LRB-4215/1
2	2	JAM:cjs&emw
3	3	2023 - 2024 LEGISLATURE
4	4	2023 ASSEMBLY BILL 753
5	5	December 6, 2023 - Introduced by Representatives GUSTAFSON, C. ANDERSON,
6	6	BROOKS, EDMING, MURPHY, SAPIK, J. ANDERSON, BARE, CONSIDINE, EMERSON,
7	7	JACOBSON, JOERS, OHNSTAD, ORTIZ-VELEZ, RATCLIFF, SHANKLAND, SINICKI and
8	8	HAYWOOD, cosponsored by Senators JAMES, HESSELBEIN, AGARD, LARSON, ROYS
9	9	and SPREITZER. Referred to Committee on Health, Aging and Long-Term Care.
10	10	*AUTHORS SUBJECT TO CHANGE*
11	11	AN ACT to create 20.285 (1) (qh), 20.285 (1) (qi), 25.14 (1) (a) 14m., 25.17 (1) (jw),
12	12	25.51 and 36.25 (16) of the statutes; relating to: creating a medicinal
13	13	psilocybin treatment fund and a pilot program to study the effects of medicinal
14	14	psilocybin treatment on patients with post-traumatic stress syndrome at the
15	15	University of Wisconsin-Madison and making an appropriation.
16	16	Analysis by the Legislative Reference Bureau
17	17	This bill creates a new separate nonlapsible trust fund designated as the
18	18	medicinal psilocybin treatment fund and establishes a pilot program to study the
19	19	effects of medicinal psilocybin treatment on patients with post-traumatic stress
20	20	syndrome (PTSD).
21	21	The medicinal psilocybin treatment pilot program created by this bill must be
22	22	established by the Board of Regents of the University of Wisconsin System at the
23	23	University of Wisconsin-Madison in collaboration with that institution's
24	24	Transdisciplinary Center for Research in Psychoactive Substances and its School of
25	25	Pharmacy. The individuals eligible to participate in the pilot program must be
26	26	veterans who are 21 years of age or older and who suffer from treatment-resistant
27	27	PTSD. Individuals who are law enforcement officers are not eligible to participate
28	28	in the pilot program study. The psilocybin therapy provided by the pilot program
29	29	must be provided through pathways approved by the federal Food and Drug
30	30	Administration, and the research accomplished in the pilot program may be
31	31	accomplished in conjunction with other medications approved by the federal Food
32	32	1
33	33	2
34	34	3
35	35	4
36	36	5 - 2 -2023 - 2024 Legislature LRB-4215/1
37	37	JAM:cjs&emw
38	38	ASSEMBLY BILL 753
39	39	and Drug Administration. The board must ensure that no health information
40	40	disclosed in the course of conducting the program contains personally identifiable
41	41	information. The researchers conducting the program must create reports for the
42	42	governor and the appropriate standing committees of the legislature regarding
43	43	progress of the pilot program and the studies conducted as part of the program.
44	44	The medicinal psilocybin treatment fund created in this bill consists of
45	45	donations, gifts, grants, bequests, moneys transferred from the general fund, and all
46	46	earnings and other investment income of the fund. This trust fund is managed by
47	47	the State of Wisconsin Investment Board. Moneys in the fund may be expended for
48	48	the purpose for which any donation, gift, grant, or bequest is made and for the
49	49	administration of the pilot program.
50	50	For further information see the state fiscal estimate, which will be printed as
51	51	an appendix to this bill.
52	52	The people of the state of Wisconsin, represented in senate and assembly, do
53	53	enact as follows:
54	54	SECTION 1. 20.005 (3) (schedule) of the statutes: at the appropriate place, insert
55	55	the following amounts for the purposes indicated:
56	56	2023-24 2024-25
57	57	20.285 University of Wisconsin System
58	58	(1) UNIVERSITY EDUCATION, RESEARCH AND PUBLIC
59	59	SERVICE
60	60	(qh)Medicinal psilocybin treatment
61	61	pilot program SEG A 100,000 -0-
62	62	SECTION 2. 20.285 (1) (qh) of the statutes is created to read:
63	63	20.285 (1) (qh) Medicinal psilocybin treatment pilot program. From the
64	64	medicinal psilocybin treatment fund, the amounts in the schedule for the operations
65	65	of the medicinal psilocybin treatment pilot program under s. 36.25 (16).
66	66	SECTION 3. 20.285 (1) (qi) of the statutes is created to read:
67	67	1
68	68	2
69	69	3
70	70	4
71	71	5
72	72	6
73	73	7
74	74	8
75	75	9
76	76	10
77	77	11
78	78	12 - 3 -2023 - 2024 Legislature
79	79	LRB-4215/1
80	80	JAM:cjs&emw
81	81	SECTION 3
82	82	ASSEMBLY BILL 753
83	83	20.285 (1) (qi) Medicinal psilocybin treatment pilot program donations, gifts,
84	84	grants, and bequests. From the medicinal psilocybin treatment fund, all moneys
85	85	received from donations, gifts, grants, and bequests to the medicinal psilocybin
86	86	treatment pilot program under s. 36.25 (16) to carry out the purpose for which
87	87	received.
88	88	SECTION 4. 25.14 (1) (a) 14m. of the statutes is created to read:
89	89	25.14 (1) (a) 14m. The medicinal psilocybin treatment fund.
90	90	SECTION 5. 25.17 (1) (jw) of the statutes is created to read:
91	91	25.17 (1) (jw) The medicinal psilocybin treatment fund (s. 25.51).
92	92	SECTION 6. 25.51 of the statutes is created to read:
93	93	25.51 Medicinal psilocybin treatment fund. There is established a
94	94	separate nonlapsible trust fund designated as the medicinal psilocybin treatment
95	95	fund. The fund shall consist of all of the following:
96	96	(1) Donations, gifts, grants, and bequests deposited into the fund under s. 36.25
97	97	(16) (b).
98	98	(2) Moneys transferred under s. 36.25 (16) (c).
99	99	(3) All earnings and other investment income of the fund.
100	100	SECTION 7. 36.25 (16) of the statutes is created to read:
101	101	36.25 (16) MEDICINAL PSILOCYBIN TREATMENT PILOT PROGRAM. (a) 1. The board
102	102	shall establish at the University of Wisconsin-Madison in collaboration with that
103	103	institution's transdisciplinary center for research in psychoactive substances and its
104	104	school of pharmacy a pilot program to study the effects of medicinal psilocybin
105	105	treatment on patients with post-traumatic stress syndrome and related
106	106	comorbidities.
107	107	1
108	108	2
109	109	3
110	110	4
111	111	5
112	112	6
113	113	7
114	114	8
115	115	9
116	116	10
117	117	11
118	118	12
119	119	13
120	120	14
121	121	15
122	122	16
123	123	17
124	124	18
125	125	19
126	126	20
127	127	21
128	128	22
129	129	23
130	130	24 - 4 -2023 - 2024 Legislature LRB-4215/1
131	131	JAM:cjs&emw
132	132	SECTION 7 ASSEMBLY BILL 753
133	133	2. The individuals eligible for the pilot program under subd. 1. shall be
134	134	veterans, as defined by the board, who are 21 years of age or older and who suffer
135	135	from treatment-resistant post-traumatic stress syndrome. An individual who is a
136	136	law enforcement officer, as defined in s. 165.85 (2) (c), or a tribal law enforcement
137	137	officer, as defined in s. 165.85 (2) (g), may not participate in the pilot program under
138	138	subd. 1.
139	139	3. The pilot program under subd. 1. shall provide psilocybin therapy through
140	140	pathways approved by the federal food and drug administration.
141	141	4. The pilot program under subd. 1. may accomplish its research in conjunction
142	142	with other medications approved by the federal food and drug administration.
143	143	5. The board shall ensure that no health information disclosed by the pilot
144	144	program under subd. 1. contains personally identifiable information, as defined
145	145	under s. 19.62 (5).
146	146	6. On the first day of the 6th month beginning after the effective date of this
147	147	subdivision .... [LRB inserts date], and every 6 months thereafter while the pilot
148	148	program under subd. 1. continues, the board shall submit to the governor and to the
149	149	appropriate standing committees of the legislature under s. 13.172 (3) a report
150	150	prepared by the researchers conducting the pilot program that details the progress
151	151	of the pilot program's study.
152	152	7. Within 6 months of the completion of a study in the pilot program under subd.
153	153	1., the board shall submit to the governor and to the appropriate standing
154	154	committees of the legislature under s. 13.172 (3) a report prepared by the researchers
155	155	conducting the study detailing the results of the study and any recommendations for
156	156	legislation based on the study results.
157	157	1
158	158	2
159	159	3
160	160	4
161	161	5
162	162	6
163	163	7
164	164	8
165	165	9
166	166	10
167	167	11
168	168	12
169	169	13
170	170	14
171	171	15
172	172	16
173	173	17
174	174	18
175	175	19
176	176	20
177	177	21
178	178	22
179	179	23
180	180	24 - 5 -2023 - 2024 Legislature
181	181	LRB-4215/1
182	182	JAM:cjs&emw
183	183	SECTION 7
184	184	ASSEMBLY BILL 753
185	185	8. Within 6 months of the completion of the pilot program under subd. 1., the
186	186	board shall submit to the governor and to the appropriate standing committees of the
187	187	legislature under s. 13.172 (3) a report prepared by the researchers conducting the
188	188	pilot program detailing the final results of the pilot program and any
189	189	recommendations for legislation based on the pilot program's results.
190	190	(b) The board, the University of Wisconsin-Madison, the University of
191	191	Wisconsin-Madison's school of pharmacy and the program under par. (a) 1. may
192	192	receive donations, gifts, grants, and bequests to the program and use any donation,
193	193	gift, grant, or bequest for the purpose for which it is made. The board shall deposit
194	194	the amount of any donation, gift, grant, or bequest into the medicinal psilocybin
195	195	treatment fund.
196	196	(c) The secretary of administration shall annually transfer from the general
197	197	fund to the medicinal psilocybin treatment fund the amount in the schedule under
198	198	20.285 (1) (qh) for the applicable fiscal year.
199	199	(END)
200	200	1
201	201	2
202	202	3
203	203	4
204	204	5
205	205	6
206	206	7
207	207	8
208	208	9
209	209	10
210	210	11
211	211	12
212	212	13
213	213	14
214	214	15